FDA actions, approvals, policy shifts and compliance: how the rules change timelines and probability.
Page 5 of 40
Sep 19, 2026The expansion turns ACCESS from a narrower chronic care experiment into a much broader reimbursement channel for remote monitoring, virtual care and connected services. For providers and digital health companies, the signal is less about a single technology than about CMS creating more room to get paid for continuous care outside fee-for-service visits.
Sep 19, 2026The new Metrix COVID test is cleared for over-the-counter use and professional use in CLIA-waived settings, broadening how Aptitude can sell and place the product. The regulatory shift matters because diagnostics companies still relying on emergency authorizations face a narrowing window as the EUA framework winds down.
Sep 19, 2026China’s Ministry of Industry and Information Technology has published a 2026 through 2030 biotechnology plan that aims to turn domestic innovation into global commercial scale. The targets span drug origination, industry growth, company revenue and blockbuster product creation, giving investors and partners a clearer view of how aggressively Beijing intends to back the sector.
Speaking at a conference hosted by the anti-vaccine nonprofit he helped start, Robert F. Kennedy Jr. said the Department of Health and Human Services is researching more than 150 serious adverse events reported after vaccination and pursuing multiple related initiatives across agencies. The remarks came with repeated claims about vaccine risk that the source says were made without evidence, alongside a renewed emphasis that he has support from President Trump.
Sep 14, 2026A Monday FDA hearing on psychedelic drug development is being framed by analysts as the next step in a broader federal push to move more of these therapies toward market. The discussion comes after updated FDA guidance in July, an April executive order from President Donald Trump, and permanent appointments for Michael Davis and Karim Mikhail at CDER and CBER.
Sep 14, 2026The White House has said its plan would save Medicare $26 billion over several years by tying U.S. prices to the lowest prices paid in 19 other wealthy nations. But the analysis points to a central execution risk: side deals may blunt the rebate structure before detailed rules for the pilot programs are released.
Sep 12, 2026The challenged provision sits inside a revised urban wastewater directive that took effect early last year. It was designed to protect human health and the environment from harmful discharges and was projected to save about $7.5 billion annually by 2040.
Mikhail and Davis had been leading CBER and CDER on an acting basis since mid-May after the departures of Vinay Prasad and Tracy Beth Høeg. In the same set of changes, Jared Seehafer was named the first Deputy Commissioner for Technology and Artificial Intelligence.
Sep 12, 2026The outbreak dominated an unprecedented rise in cyclospora infections this year and was tied to iceberg lettuce recalled by Taylor Farms after investigators focused on a processing chain in Mexico. The immediate event may be over, but the unresolved contamination pathway leaves a policy problem for import oversight and outbreak prevention.
Sep 11, 2026Exelixis said in a Securities and Exchange Commission filing that the FDA asked for more time while it awaits updated safety and efficacy data for zanzalintinib in combination with Roche’s Tecentriq in metastatic colorectal cancer. The new decision date is March 2027 instead of Dec. 3, 2026, extending uncertainty around an application that was already under pressure after a missed primary endpoint in June.
Sep 11, 2026The new guidance lets states classify diagnoses by how likely they are to impair a person’s ability to work or volunteer at least 20 hours per week. It offers a clearer path to automatic exemptions for some patients, while leaving major execution risk as expansion states race toward implementation deadlines and a legal challenge continues.
Sep 11, 2026The boycott follows the forced removal of five scientists from the ADA’s annual conference after they distributed an editorial criticizing the Trump administration’s cuts to federal science spending. The association first said the removals were tied to conduct that disrupted the event and violated its attendee code, then later said its initial findings had not captured the full breadth and depth of the investigation.
Machine learning, predictive models and computational biology: how AI is changing discovery workflows and probability of success.
Drug development, clinical trials and industry dynamics. What changes timelines, risk and competitive positioning.
Gene therapy, CRISPR, synthetic biology and emerging platforms. Separating what is real from what is hype, and what actually translates.
Where capital is flowing and why the tape moves, across funding rounds, M&A, IPOs and market analysis.
Digital health, diagnostics and medical devices, and the signals that matter for adoption, reimbursement and outcomes.